Edition:
United States

Illumina Inc (ILMN.OQ)

ILMN.OQ on NASDAQ Stock Exchange Global Select Market

331.44USD
4:00pm EDT
Change (% chg)

$5.45 (+1.67%)
Prev Close
$325.99
Open
$326.12
Day's High
$334.00
Day's Low
$326.12
Volume
249,348
Avg. Vol
336,011
52-wk High
$341.08
52-wk Low
$189.34

Latest Key Developments (Source: Significant Developments)

Illumina Announces Pricing Of Convertible Senior Notes
Thursday, 16 Aug 2018 08:28pm EDT 

Aug 16 (Reuters) - Illumina Inc ::ILLUMINA ANNOUNCES PRICING OF CONVERTIBLE SENIOR NOTES.ANNOUNCED PRICING OF AN OFFERING OF $650 MILLION AGGREGATE PRINCIPAL AMOUNT OF ITS 0.0% CONVERTIBLE SENIOR NOTES DUE 2023.NOTES WILL NOT BEAR INTEREST AND WILL MATURE ON AUGUST 15, 2023, UNLESS EARLIER REPURCHASED, REDEEMED OR CONVERTED..  Full Article

Illumina Sees Non-GAAP Diluted EPS Attributable To Illumina Stockholders In Range Of $4.50-$4.60 For Fiscal Year 2018
Thursday, 11 Jan 2018 06:25am EST 

Jan 11 (Reuters) - Illumina Inc ::ILLUMINA INC - SEES NON-GAAP DILUTED EPS ATTRIBUTABLE TO ILLUMINA STOCKHOLDERS IN RANGE OF $4.50 - $4.60 FOR FISCAL YEAR 2018.ILLUMINA - SEES SEES GAAP DILUTED EPS ATTRIBUTABLE TO ILLUMINA STOCKHOLDERS IN RANGE OF $4.14 - $4.24 FOR FISCAL YEAR 2018- SEC FILING.  Full Article

HTG Molecular, Illumina Agreed To Third Development Plan Under Parties' Amended & Restated Development & Supply Agreement
Wednesday, 27 Dec 2017 04:35pm EST 

Dec 27 (Reuters) - HTG Molecular Diagnostics Inc ::HTG MOLECULAR DIAGNOSTICS - ON DEC 23, CO, ILLUMINA AGREED TO THIRD DEVELOPMENT PLAN UNDER PARTIES' AMENDED & RESTATED DEVELOPMENT & SUPPLY AGREEMENT.HTG MOLECULAR DIAGNOSTICS SAYS UNDER PLAN, ILLUMINA EXPECTED TO DEVELOP & DELIVER TO CO EXECUTABLE VERSION OF CUSTOM SOFTWARE - SEC FILING.  Full Article

Luna Dna Announces $2 Mln In Seed Funding Round Included Several Individual Investors And Former Executives From Illumina
Monday, 18 Dec 2017 05:15pm EST 

Dec 18 (Reuters) - Illumina Inc ::LUNA DNA ANNOUNCES $2 MILLION IN SEED FUNDING; ROUND INCLUDED SEVERAL INDIVIDUAL INVESTORS AND FORMER EXECUTIVES FROM ILLUMINA.  Full Article

Disney Board Elects Oracle And Illumina CEOs As Directors
Thursday, 7 Dec 2017 04:15pm EST 

Dec 7 (Reuters) - Walt Disney Co ::DISNEY BOARD ELECTS ORACLE’S SAFRA CATZ AND ILLUMINA’S FRANCIS A. DESOUZA AS DIRECTORS.WALT DISNEY CO - ELECTIONS OF CATZ AND DESOUZA ARE EFFECTIVE FEBRUARY 1, 2018.WALT DISNEY CO - ELECTION OF 2 NEW DIRECTORS: SAFRA CATZ, CEO OF ORACLE, AND FRANCIS DESOUZA, CEO OF BIOTECHNOLOGY FIRM ILLUMINA INC.  Full Article

Illumina reports Q3 GAAP earnings per share $1.11
Tuesday, 24 Oct 2017 04:05pm EDT 

Oct 25 (Reuters) - Illumina Inc :Illumina reports financial results for third quarter of fiscal year 2017.Q3 non-GAAP earnings per share $1.11.Q3 GAAP earnings per share $1.11.Q3 revenue $714 million versus I/B/E/S view $692.8 million.Sees fy 2017 non-GAAP earnings per share $3.73 to $3.78.Sees fy 2017 revenue up about 13 percent.Q3 earnings per share view $0.99 -- Thomson Reuters I/B/E/S.Illumina Inc - ‍for fiscal 2017 company now projects GAAP earnings per diluted share attributable to Illumina stockholders of $5.56 to $5.61​.Fy2017 earnings per share view $3.65, revenue view $2.68 billion -- Thomson Reuters I/B/E/S.  Full Article

Illumina files new patent infringement suit against Premaitha Health Plc
Thursday, 7 Sep 2017 09:00am EDT 

Sept 7 (Reuters) - Illumina Inc :Illumina Inc - ‍filed new patent infringement suit against Premaitha Health Plc in High Court of Justice, Chancery Division, Patents Court in UK.  Full Article

Illumina Q2 earnings per share $0.87
Tuesday, 1 Aug 2017 04:05pm EDT 

Aug 1 (Reuters) - Illumina Inc :Illumina reports strong financial results for second quarter of fiscal year 2017.Q2 non-GAAP earnings per share $0.82.Q2 GAAP earnings per share $0.87.Q2 revenue $662 million versus I/B/E/S view $642.4 million.Q2 earnings per share view $0.69 -- Thomson Reuters I/B/E/S.Illumina Inc says for fiscal 2017, company has updated its projections to approximately 12% revenue growth.Illumina Inc says for fy 2017 gaap earnings per diluted share attributable to illumina stockholders is forecasted to be $5.36 to $5.46.Illumina Inc says expects FY 2017 non-GAAP earnings per diluted share attributable to illumina stockholders of $3.60 to $3.70.Fy2017 earnings per share view $3.63, revenue view $2.65 billion -- Thomson Reuters I/B/E/S.  Full Article

Inno-Gene says units reach agreement with Illumina over patent dispute
Monday, 26 Jun 2017 02:54am EDT 

June 26 (Reuters) - INNO-GENE SA ::SAID ON FRIDAY THAT ITS UNITS, CENTRUM BADAN DNA SP. Z O.O AND MEDGENETIX SP. Z O.O., REACHED SETTLEMENT WITH THE COMPANY ILLUMINA INC. <<>> CONCERNING VIOLATION OF INTELLECTUAL PROPERTY OF ITS PATENT.SAID ITS UNITS AFFIRMED VALIDITY OF ILLUMINA INC. PATENT AND ILLUMINA INC. WILL WITHDRAW THE LAWSUIT.  Full Article

HTG Molecular amends, restates IVD test development, component supply agreement with Illumina
Monday, 5 Jun 2017 08:00am EDT 

June 5 (Reuters) - HTG Molecular Diagnostics Inc ::Amended and restated its IVD test development and component supply agreement with Illumina.HTG Molecular Diagnostics - agreement extends term, increases number of in-vitro diagnostic test kits that may be developed with Illumina sequencing technology.  Full Article

BRIEF-Illumina Acquires Edico Genome To Accelerate Genomic Data Analysis

* ILLUMINA ACQUIRES EDICO GENOME TO ACCELERATE GENOMIC DATA ANALYSIS Source text for Eikon: Further company coverage: